LU91658I2 - Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, poliomyélitique et Haemophilus influenzae type B conjugué (INFANRIX HEXA®) - Google Patents

Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, poliomyélitique et Haemophilus influenzae type B conjugué (INFANRIX HEXA®)

Info

Publication number
LU91658I2
LU91658I2 LU91658C LU91658C LU91658I2 LU 91658 I2 LU91658 I2 LU 91658I2 LU 91658 C LU91658 C LU 91658C LU 91658 C LU91658 C LU 91658C LU 91658 I2 LU91658 I2 LU 91658I2
Authority
LU
Luxembourg
Prior art keywords
poliomyelitis
pertussis
tetanus
hepatitis
haemophilus influenzae
Prior art date
Application number
LU91658C
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91658(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929211081A external-priority patent/GB9211081D0/en
Priority claimed from GB929213308A external-priority patent/GB9213308D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of LU91658I2 publication Critical patent/LU91658I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
LU91658C 1992-05-23 2010-03-03 Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, poliomyélitique et Haemophilus influenzae type B conjugué (INFANRIX HEXA®) LU91658I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211081A GB9211081D0 (en) 1992-05-23 1992-05-23 Vaccines
GB929213308A GB9213308D0 (en) 1992-06-23 1992-06-23 Vaccine

Publications (1)

Publication Number Publication Date
LU91658I2 true LU91658I2 (fr) 2010-05-03

Family

ID=26300928

Family Applications (2)

Application Number Title Priority Date Filing Date
LU91659C LU91659I2 (fr) 1992-05-23 2010-03-03 Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, et poliomyélitique (INFANRIX PENTA®)
LU91658C LU91658I2 (fr) 1992-05-23 2010-03-03 Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, poliomyélitique et Haemophilus influenzae type B conjugué (INFANRIX HEXA®)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU91659C LU91659I2 (fr) 1992-05-23 2010-03-03 Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, et poliomyélitique (INFANRIX PENTA®)

Country Status (31)

Country Link
US (1) US6013264A (fr)
EP (4) EP0642355B1 (fr)
JP (1) JP3626996B2 (fr)
KR (1) KR100287083B1 (fr)
CN (2) CN1313152C (fr)
AP (1) AP567A (fr)
AT (2) ATE168271T1 (fr)
AU (5) AU4315693A (fr)
CA (1) CA2136429C (fr)
CY (1) CY2614B2 (fr)
CZ (1) CZ283910B6 (fr)
DE (4) DE122010000016I1 (fr)
DK (2) DK0835663T3 (fr)
ES (2) ES2118963T3 (fr)
FI (1) FI945483A (fr)
HK (2) HK1011290A1 (fr)
HU (1) HU220236B (fr)
IL (1) IL105770A (fr)
LU (2) LU91659I2 (fr)
MA (1) MA22894A1 (fr)
MX (1) MX9302982A (fr)
MY (1) MY110665A (fr)
NO (1) NO309675B1 (fr)
NZ (1) NZ253065A (fr)
PT (1) PT835663E (fr)
RU (1) RU2160120C2 (fr)
SG (1) SG48365A1 (fr)
SI (1) SI9300271A (fr)
SK (1) SK280702B6 (fr)
UA (1) UA40596C2 (fr)
WO (1) WO1993024148A1 (fr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
DE69612198T3 (de) 1995-06-23 2011-08-18 Smithkline Beecham Biologicals S.A. Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
ATE339965T1 (de) * 1996-07-02 2006-10-15 Aventis Pasteur Vielwertige dtp-polio-impfstoffe
US20010014331A1 (en) 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
CA2288129A1 (fr) * 1997-05-01 1998-11-12 Chiron Corporation Utilisation de particules de type viral en tant qu'adjuvants
DE69735191T2 (de) * 1997-09-15 2006-10-05 Sanofi Pasteur Msd Verfahren zur Herstellung multivalenter Impfstoffe
PL343429A1 (en) * 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
RU2130779C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
EP1588714A2 (fr) 1998-10-16 2005-10-26 GlaxoSmithKline Biologicals S.A. Produits d'adjuvant et vaccins
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US7098309B2 (en) * 1998-12-23 2006-08-29 Merck & Co., Inc. Recombinant hepatitis B surface antigen
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
NZ622900A (en) * 2001-01-23 2015-11-27 Sanofi Pasteur Inc Multivalent meningococcal polysaccharide-protein conjugate vaccine
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (fr) * 2001-07-26 2012-04-17 Chiron S.R.L. Vaccins comprenant des adjuvants aluminium et histidine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
ES2379346T3 (es) * 2002-03-28 2012-04-25 Brenntag Biosector A/S Composiciones de vacuna combinadas de ADN/proteína
GB0223355D0 (en) * 2002-10-08 2002-11-13 Chiron Spa Vaccine
BR0315767A (pt) 2002-11-01 2005-09-06 Glaxosmithkline Biolog Sa Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1961426E (pt) 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Vacinas combinadas contra a meningite
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
WO2005117965A1 (fr) 2004-06-04 2005-12-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methodes pour preparer des conjugues immunogeniques
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
RU2442825C2 (ru) 2005-04-18 2012-02-20 Новартис Вэксинес Энд Дайэгностикс Инк. Иммуногенные композиции, способы получения таких композиций и плазмида, включенная в такие композиции
AU2006263965B2 (en) 2005-06-27 2012-09-13 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
GB0517719D0 (en) * 2005-08-31 2005-10-05 Chiron Srl Vaccines containing pili
EP1931380A2 (fr) 2005-09-01 2008-06-18 Novartis Vaccines and Diagnostics GmbH & Co. KG Vaccination multiple comprenant des meningocoques du serogroupe c
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1862176A1 (fr) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Procédé de production de composition vaccinale
EP1862177A1 (fr) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Procédé de production de composition vaccinale
GB0616226D0 (en) * 2006-08-15 2006-09-27 Novartis Ag Processes
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
EP2491947A3 (fr) 2006-09-07 2012-10-17 GlaxoSmithKline Biologicals S.A. Vaccin
EP2114991A1 (fr) * 2007-02-07 2009-11-11 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Antigenes recombinants du cytomegalovirus humain (hcmv)
EP2682127A1 (fr) 2007-05-02 2014-01-08 GlaxoSmithKline Biologicals S.A. Vaccin
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
WO2012072088A1 (fr) 2010-12-02 2012-06-07 Bionor Immuno As Conception d'échafaudage peptidique
EP2661277A2 (fr) 2011-01-05 2013-11-13 Bharat Biotech International Limited Vaccin heptavalent combiné
MX346475B (es) 2011-01-06 2017-03-22 Bionor Immuno As Peptidos inmunogenicos monomericos y multimericos.
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
KR20140066126A (ko) * 2011-05-11 2014-05-30 리스벡 헬스케어 스웨덴 에이비 단백질 f - 라미닌 및 비트로넥틴 결합 특성을 갖는 신규한 헤모필러스 인플루엔자 부착분자
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (fr) 2011-11-11 2013-05-15 Novartis AG Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
CA2862560A1 (fr) 2012-02-01 2013-08-08 Glaxosmithkline Biologicals S.A. Procede de fermentation de l'espece bordetella
CN104159603A (zh) * 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
AU2013273482A1 (en) 2012-06-06 2014-12-11 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
JP2015525794A (ja) 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2886938A1 (fr) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Antigenes de pertussis acellulaires non reticules pour leur utilisation dans des vaccins combines
AP2015008702A0 (en) 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
US9993534B2 (en) 2013-03-12 2018-06-12 Wisconsin Alumni Research Foundation Method of treating fungal infection
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
WO2016012385A1 (fr) 2014-07-21 2016-01-28 Sanofi Pasteur Composition de vaccin comprenant du pvi et des cyclodextrines
MA42317B2 (fr) * 2015-09-16 2021-11-30 Lg Chemical Ltd Composition de vaccin combinée pour administration multiple
EP3518968B1 (fr) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Immunogènes de peptides de fusion env du vih-1 et leur utilisation
WO2018081832A1 (fr) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fragments peptidiques de filovirus et leurs utilisations
EP3600405A1 (fr) 2017-03-24 2020-02-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Domaines externes modifiés masqués par le glycane du vih-1, gp120, et leur utilisation
EA202090316A1 (ru) 2017-07-18 2020-12-08 Серум Инститьют Оф Индия Пвт Лтд. Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения
WO2019079337A1 (fr) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines d'enveloppe recombinées du vih-1 et leur utilisation
WO2020043874A1 (fr) 2018-08-31 2020-03-05 Glaxosmithkline Biologicals Sa Vaccin conjugué contre haemophilus influenzae utilisant une vésicule de membrane externe de bordetella
WO2020061564A1 (fr) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugués de vecteur à nanoparticules de peptide de fusion env du vih-1 et utilisation de ces derniers
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020086483A1 (fr) 2018-10-22 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéine gp120 de recombinaison à délétion de la boucle v1
EP3972637A4 (fr) 2019-05-20 2023-06-21 Soligenix, Inc. Compositions et procédés de fabrication de vaccins anti-filovirus trivalents
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
WO2021176409A1 (fr) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Combinaison de conservateurs pour composition de vaccin
WO2022224966A1 (fr) * 2021-04-20 2022-10-27 Ｋｍバイオロジクス株式会社 Composition vaccinale hexavalente liquide
EP4380613A1 (fr) 2021-08-03 2024-06-12 The United States of America, as represented by the Secretary, Department of Health and Human Services Vaccination contre le vih-1 et microbicide samt-247 pour prévenir une infection par le vih-1
EP4169513A1 (fr) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Composition d'adjuvant comprenant des agonistes du sting
WO2023192835A1 (fr) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ectodomaines de l'enveloppe du vih-1 recouverts d'une base et leur utilisation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
EP0304578B1 (fr) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide contenant l'antigène de surface de l'hépatite B
EP0299108B1 (fr) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH Molécules d'ADN codant pour les régions de contrôle de FMDH et gène structurel pour une protéine ayant l'activité du FMDH et leur utilisation
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
DK0427462T3 (da) 1989-11-06 1996-03-11 Smithkline Beecham Biolog Fremgangsmåde
AU646019B2 (en) 1990-02-12 1994-02-03 Smithkline Beecham Biologicals (Sa) Novel vaccine and method therefor
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
EP0563091A1 (fr) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B
CA2067003A1 (fr) 1991-04-29 1992-10-30 Peter J. Kniskern Vaccin mutant de variante d'antigene de surface d'hbv
JPH06503231A (ja) * 1991-09-18 1994-04-14 アムジエン・インコーポレーテツド 胆汁酸塩を含有するｂ型肝炎ワクチン製剤
SK117395A3 (en) * 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
DE69612198T3 (de) 1995-06-23 2011-08-18 Smithkline Beecham Biologicals S.A. Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
RU2130778C1 (ru) 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법

Also Published As

Publication number Publication date
EP0835663B1 (fr) 2009-09-30
NO309675B1 (no) 2001-03-12
AP567A (en) 1996-11-25
LU91659I2 (fr) 2010-05-03
IL105770A0 (en) 1993-09-22
IL105770A (en) 1998-08-16
EP0835663A2 (fr) 1998-04-15
SK142194A3 (en) 1995-08-09
CN1136918C (zh) 2004-02-04
AU2010200249B2 (en) 2012-01-12
RU94046145A (ru) 1997-03-27
EP2289548A3 (fr) 2012-08-08
EP2289548A2 (fr) 2011-03-02
JP3626996B2 (ja) 2005-03-09
EP0835663A3 (fr) 1999-03-03
AU4315693A (en) 1993-12-30
HK1021142A1 (en) 2000-06-02
HK1011290A1 (en) 1999-07-09
RU2160120C2 (ru) 2000-12-10
CZ289294A3 (en) 1995-09-13
KR950701822A (ko) 1995-05-17
HU220236B (hu) 2001-11-28
MA22894A1 (fr) 1993-12-31
DE69319728D1 (de) 1998-08-20
HU9403366D0 (en) 1995-02-28
CA2136429A1 (fr) 1993-12-09
AU2007201162A1 (en) 2007-04-19
SI9300271A (en) 1993-12-31
MY110665A (en) 1999-01-30
FI945483A0 (fi) 1994-11-22
AU5062902A (en) 2002-08-08
CA2136429C (fr) 2001-12-11
AU709406B2 (en) 1999-08-26
ES2334181T3 (es) 2010-03-05
EP2156845A1 (fr) 2010-02-24
AP9300530A0 (en) 1993-07-31
EP0642355A1 (fr) 1995-03-15
CN1085450A (zh) 1994-04-20
KR100287083B1 (ko) 2001-04-16
SG48365A1 (en) 1998-04-17
SK280702B6 (sk) 2000-06-12
FI945483A (fi) 1995-01-20
US6013264A (en) 2000-01-11
CZ283910B6 (cs) 1998-07-15
DE122010000015I1 (de) 2010-07-08
NO944475L (no) 1995-01-18
JPH07508267A (ja) 1995-09-14
ATE168271T1 (de) 1998-08-15
WO1993024148A1 (fr) 1993-12-09
ATE444079T1 (de) 2009-10-15
AU2010200249A1 (en) 2010-02-11
DE69319728T2 (de) 1999-02-04
PT835663E (pt) 2010-01-04
AU709406C (en) 2004-04-08
DE69334297D1 (de) 2009-11-12
NO944475D0 (no) 1994-11-22
CN1623602A (zh) 2005-06-08
CY2614B2 (en) 2012-01-25
ES2118963T3 (es) 1998-10-01
AU1648097A (en) 1997-05-29
NZ253065A (en) 1996-10-28
HUT71791A (en) 1996-02-28
CN1313152C (zh) 2007-05-02
MX9302982A (es) 1993-12-01
UA40596C2 (uk) 2001-08-15
DK0642355T3 (da) 1998-11-30
AU785433B2 (en) 2007-05-31
EP0642355B1 (fr) 1998-07-15
DE122010000016I1 (de) 2010-07-08
DK0835663T3 (da) 2010-02-01

Similar Documents

Publication Publication Date Title
LU91658I2 (fr) Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, poliomyélitique et Haemophilus influenzae type B conjugué (INFANRIX HEXA®)
AR243934A1 (es) Un metodo para obtener n-alcanoil(c4-c8)gbmp a partir de gbmp n-desacetilado y metodo para preparar conjugados de proteinas inmunologicas con dicho producto n-desacetilado.
HU1000594D0 (en) Vaccine composition
DK0633784T4 (da) Hepatitisvacciner indeholdende 3-O-deacyleret monophosphoryl-lipid A
NZ302674A (en) Hepatitis b vaccine with hepatitis b antigen, 3-o-deacylated monophosphoryl lipid a, and aluminium phosphate
DK0689454T3 (da) Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
DK0750907T3 (da) Stabile vaccinepræparater til parenteral administrering, en fremgangsmåde til deres anvendelse og en fremgangsmåde til deres fremstilling
NO2006005I1 (no) Difteri-,tetanus-, acellulære kikhoste- og polioantigener
DK0914153T3 (da) Multivalente DTP-poliovacciner
PT1028750E (pt) Metodo de preparacao de vacinas polivalentes
DZ1706A1 (fr) Vaccin contre le virus de l'hepatite a.
AU2001269569A1 (en) Quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis surface antigen, and preparation method thereof
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
EP0647139A4 (fr) VACCIN CONJUGUE ADHESINE-OLIGOSACCHARIDE CONTRE -i(HAEMOPHILUS INFLUENZAE).
GB9611501D0 (en) Vaccine compositions
PL346645A1 (en) IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
HU0400424D0 (en) Hepatitis virus vaccines
NO920160D0 (no) Cytokin- og hormonbaerere for konjugatvaksiner
SI0810877T1 (en) Hepatitis b vaccine
RU95121713A (ru) Способ одновременной профилактики менингококковой инфекции, дифтерии, брюшного тифа, натуральной оспы, гриппа и вирусного гепатита
IL143675A0 (en) Hepatitis c virus infection diagnostics and vaccines
SG48106A1 (en) Pneumococcal polyaccharide conjugate vaccine
GB9503395D0 (en) Viral,preparations,immunogens,and vaccines
ZA965274B (en) A vaccine comprising a polysaccharide-antigen conjugate from haemophilus influenzae type b adsorbed onto aluminium phosphate and its use in combination vaccines